Core Insights - Village Farms reported strong financial performance for Q4-2025, driven by international exports and sales in the Netherlands [1] - The company has expanded its grow facilities in Canada and the Netherlands, which is expected to lead to higher revenue in 2026 [1] Financial Performance - The financial results for Q4-2025 indicate robust growth, particularly from international markets [1] - Sales in the Netherlands are a significant contributor to the company's overall performance [1] Expansion Plans - Village Farms is actively expanding its growing facilities in both Canada and the Netherlands [1] - This expansion is anticipated to enhance revenue generation capabilities over the upcoming year [1]

Core Insights - The article emphasizes the importance of identifying undervalued stocks that are mispriced by the market, particularly as the end of Q1 approaches [1]. Group 1: Company Overview - Stone Fox Capital is an RIA based in Oklahoma, led by Mark Holder, a CPA with extensive experience in investing and portfolio management [2]. - Mark Holder has 30 years of investing experience, including 15 years as a portfolio manager, and leads the investing group Out Fox The Street [2]. Group 2: Services Offered - The investing group provides stock picks and in-depth research aimed at uncovering potential multibaggers while managing portfolio risk through diversification [2]. - Features of the service include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct communication with Mark for inquiries [2].

Market Position and Expansion - Village Farms maintained a top five overall market share position in Canada and held the number one position in dried flower as of February 2026, despite planned reductions in sales of lower-margin SKUs [412]. - International export sales increased 517% year-over-year, driven by strong demand in Germany and steady performance across other international markets [417]. - The expansion of cultivation capacity in the Delta 2 greenhouse is expected to yield an incremental 40 metric tons of annualized cannabis production, expanding capacity by approximately 33% once completed [412]. - The Phase II facility in Groningen is nearing completion and is expected to quintuple total annualized production to approximately 10,000 kilograms when fully operational [417]. - The Company believes it remains the largest exporter of medical cannabis to Europe, with three of the top five leading cultivars in Germany [417]. - The acquisition of the remaining 15% equity ownership interest in Leli Holland was completed in September 2024, allowing the Company to cultivate and distribute cannabis legally in the Netherlands [393]. - The Company's application for a Texas medicinal marijuana license remains under review, with DPS required to award a minimum of three new licenses on or before April 1, 2026 [417]. Financial Performance - Sales for the year ended December 31, 2025 increased by $20,030, or approximately 10%, to $215,937 from $195,907 for the year ended December 31, 2024 [422]. - Cost of sales for the year ended December 31, 2025 decreased by $21,851, or 15%, to $128,255 from $150,106 for the year ended December 31, 2024 [423]. - Gross profit for the year ended December 31, 2025 increased by $41,881, or 91%, to $87,682 from $45,801 for the year ended December 31, 2024 [424]. - Selling, general and administrative expenses for the year ended December 31, 2025 decreased by $1,455 to $60,293, or 28% of sales, from $61,748, or 32% of sales, for the year ended December 31, 2024 [425]. - Net income attributable to Village Farms International, Inc. shareholders for the year ended December 31, 2025 was $32,441, compared to a loss of $35,851 for the year ended December 31, 2024, an increase of $68,292 [436]. - Adjusted EBITDA from continuing operations for the year ended December 31, 2025 increased by $42,478 to $49,852 from $7,374 for the year ended December 31, 2024 [437]. - Income before taxes for the year ended December 31, 2025 was $31,359 compared to a loss of $29,604 for the year ended December 31, 2024, an increase of $60,963 [432]. - Other income for the year ended December 31, 2025 was $4,173 compared to $4,015 for the year ended December 31, 2024 [430]. - The net income (loss) including non-controlling interests for the year ended December 31, 2025, was $32,105 [453]. - Basic income (loss) per share from continuing operations for the year ended December 31, 2025, was $0.01 [453]. - Diluted income (loss) per share for the year ended December 31, 2025, was $0.10 [453]. Cost Management - The company incurred excise duties of $59,950 (C$83,744) for the year ended December 31, 2025, representing 38% of gross branded sales, a decrease from 39% in 2024, due to lower kilograms sold in the branded channel [461]. - Selling, general and administrative expenses for the year ended December 31, 2025 increased by $844, or 2%, to $34,872, representing 21% of net sales, compared to 23% in 2024 [467]. - U.S. Cannabis selling, general and administrative expenses for the year ended December 31, 2025 decreased by $2,405 to $9,585, or 66% of sales, from $11,990, or 69% of sales, for the year ended December 31, 2024 [489]. - Share-based compensation expenses were $1,741 thousand in 2025, down from $3,747 thousand in 2024, reflecting a potential cost management strategy [541]. Operational Challenges - The Canadian Cannabis segment continues to face challenges with excise taxes, which remain the largest cost in the branded adult-use market, impacting overall profitability [461]. - U.S. Cannabis net sales for the year ended December 31, 2025 decreased by $2,951, or 17%, to $14,439 from $17,390 for the year ended December 31, 2024 [485]. - U.S. Cannabis gross profit for the year ended December 31, 2025 was $9,023, representing a 63% gross margin, compared to $11,035 and a 66% gross margin for the year ended December 31, 2024 [488]. - U.S. Cannabis net loss for the year ended December 31, 2025 was $782 compared to a loss of $13,333 for the year ended December 31, 2024, showing significant improvement [491]. - U.S. Cannabis Adjusted EBITDA from continuing operations for the year ended December 31, 2025 was ($288) compared to ($672) for the year ended December 31, 2024, indicating improved operational efficiency [492]. Asset Management - The company recorded goodwill and intangible impairments of $11,939 thousand in 2024 and $14,020 thousand in 2023, which were not present in 2025, suggesting improved asset management [541]. - The company reported a net income from continuing operations of $20,988 thousand for the year ended December 31, 2025, compared to a net loss of $27,942 thousand in 2024 [543]. - The cannabis segment in Canada generated a net income of $26,241 for 2025, a significant improvement from a loss of $2,814 in 2024 [543]. - The corporate segment reported a net loss of $8,761 in 2025, compared to a loss of $7,490 in 2024, highlighting ongoing challenges [543]. Cash Flow and Financing - As of December 31, 2025, the company had $86,252 in cash and cash equivalents, significantly up from $24,631 as of December 31, 2024 [520]. - Cash flow from operating activities for the year ended December 31, 2025, was $58,112, significantly up from $13,728 in 2024 [534]. - Cash used in investing activities for 2025 was $18,614, primarily due to capital expenditures of $11,624 for the Cannabis Netherlands Phase II facility [535]. - Financing activities for 2025 resulted in a net cash outflow of $6,351, including net repayments on borrowings of $7,865 [536]. - The outstanding amount of the Pure Sunfarms Term Loan Facility was $17,799 as of December 31, 2025, with quarterly repayments of C$1.0 million [528]. - The Company entered into a secured credit facility with a Canadian bank on April 17, 2025, with an aggregate borrowing capacity of C$37.4 million, including a C$10.0 million revolving credit facility and a C$27.4 million term loan [527]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming fiscal year to improve financial performance [454]. - The company anticipates a compound annual revenue growth rate of 7.5% from 2025 to 2029 for its Canadian Cannabis segment [553]. - The company anticipates an average revenue growth rate of 8% over the next 6 years, followed by a terminal growth rate of 4.1% [569]. - The company plans to increase its interest in Rose LifeScience to 80% starting April 1, 2024, and to 100% in Leli beginning September 23, 2024, indicating a strategy for market expansion [542].

Core Insights - The company has shifted its Canadian product mix towards higher-margin SKUs, achieving gross margins of 43%, consistently exceeding the long-term target range of 30% to 40% [1] - The Netherlands pilot program has been successfully commercialized, resulting in positive net income after only three quarters of revenue [1] Canadian Market Performance - Canadian cannabis performance remains a core driver, maintaining the 1 market share position in dry flower despite temporary labor-related supply chain disruptions in British Columbia [2] - International cannabis export sales have increased more than sixfold, leveraging a four-year tenure as an EU GMP-certified operator to meet tightening global regulatory standards [2] Financial Performance and Strategy - The company achieved a $49 million year-over-year improvement in net income from continuing operations, attributed to disciplined capital allocation and the privatization of legacy produce assets [3] - Record fiscal 2025 performance was driven by a 'crawl-walk-run' strategy, transitioning from a legacy produce focus to a high-margin global cannabis operator [3] - The Delta 2 facility expansion in Canada is on track to contribute 15 incremental metric tons during the remainder of 2025, with a goal of 40 additional metric tons of annual production by mid-2027 [3] - The Netherlands Phase 2 facility in Groningen is nearing completion, with planting expected in late March and full capacity of 10 metric tons anticipated to ramp up throughout the remainder of 2025 [3] Future Outlook - Management expects a return to sequential growth in international exports in Q1 2026, supported by expansion into multiple new jurisdictions over the coming months [3] - Anticipated 2026 cash flow will be impacted by approximately $16 million in Canadian income tax payments as prior carryover tax losses have been fully utilized [3] - The strategic focus for 2026 remains on balancing domestic Canadian demand with high-margin international opportunities while maintaining a growth-oriented M&A mindset [3]

Core Insights - Village Farms International reported record profitability and cash generation in fiscal 2025, driven by significant growth in global cannabis sales and international exports, alongside contributions from its Netherlands recreational cannabis business [1][4] - The company experienced a "step function transformation" in profitability and cash flow, with global cannabis sales increasing by 70% year-over-year [4] - Near-term supply constraints and shipment timing issues have created variability in quarterly performance, but management expects capacity expansions to alleviate these constraints [2][14] Financial Performance - In the fourth quarter, net sales rose 9% year-over-year to $49.6 million, with net income from continuing operations of $2.3 million and adjusted EBITDA of $8.6 million [3][6][8] - For the full year, net income from continuing operations was reported at $21 million, with adjusted EBITDA reaching $50 million and cash flow from continuing operations at $58 million [4] - Canadian cannabis net sales for the full year increased by 12% to a record $228 million, with fourth-quarter sales growing 10% year-over-year [11] International Expansion and Capacity - International exports increased more than six-fold, contributing significantly to revenue growth [1][4] - The Delta 2 expansion in Canada is expected to add approximately 15 metric tons of production in 2025 and 40 metric tons annually by mid-2027, representing a 33% increase [17] - The Netherlands Phase II facility is nearing completion, expected to bring total annual production capacity to approximately 10 metric tons [19] Strategic Milestones - The company privatized its legacy produce business in May, allowing it to retain long-term optionality tied to its greenhouse assets [5] - Management highlighted the importance of maintaining a top-five market share position in Canada, particularly in the dried flower segment [10] Cost Structure and Tax Implications - The company incurred $21.5 million in Canadian excise taxes during the fourth quarter, which accounted for nearly 40% of retail-branded sales [13] - Canadian cannabis gross margin improved to 43% in the fourth quarter, up from 3% a year ago, driven by a higher proportion of international exports and a focus on higher-margin products [12]

Financial Data and Key Metrics Changes - Village Farms reported record net income from continuing operations of $21 million or $0.19 per share, a $49 million improvement compared to the prior year [5] - Adjusted EBITDA from continuing operations reached $50 million, an improvement of $48 million year-over-year [5] - Cash flow from continuing operations was $58 million, an increase of $44 million compared to 2024 [5] - Consolidated net sales increased by 9% to $49.6 million in Q4 2025 [25] - Net income from continuing operations improved to $2.3 million, compared to a net loss of $5.7 million in Q4 of last year [26] Business Line Data and Key Metrics Changes - Global cannabis sales grew by 70% year-over-year, with significant contributions from the Netherlands business [4] - Canadian cannabis sales for Q4 were $52.7 million, a 10% increase compared to Q4 of last year [27] - International export sales increased by 384% over Q4 of last year [27] - Retail branded sales in Canada were flat compared to Q4 last year, but gross margins improved to 43% [15][28] Market Data and Key Metrics Changes - The company maintained a top five overall market share position in Canada and held the number one position in dried flower as of the end of last month [15] - The Netherlands operations generated $3.3 million in sales during Q4, with adjusted EBITDA of $700,000 [31] - Canadian cannabis gross margin was 43%, significantly up from 3% in Q4 of last year [28] Company Strategy and Development Direction - The company is focused on improving margin performance, profitability, and cash generation to enable additional growth investments [5] - Village Farms is transitioning to a more robust cannabis operation, having privatized its legacy produce business to focus on cannabis [12] - The company is investing in capacity expansion projects in Canada and the Netherlands to meet increasing demand [20][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand fundamentals domestically and internationally, expecting continued profitable growth in 2026 and beyond [19] - The company acknowledged temporary supply constraints due to a labor strike in British Columbia, which impacted Q4 sales by approximately $2.5 million [17] - Management highlighted the importance of maintaining a balanced approach to capital allocation while pursuing growth opportunities [37] Other Important Information - The company ended the year with approximately $86 million in cash, positioning it well for future investments [24] - A share repurchase program was initiated, with the purchase of approximately 813,000 shares at an aggregate cost of $3 million during Q4 [34] Q&A Session Summary Question: Share repurchases and capital allocation - Management indicated that share repurchases reflect confidence in cash generation and do not hinder business operations or growth opportunities [40] Question: Growth in the German market - Management acknowledged a decline in German import volumes but expects growth to resume in Q1, citing regulatory changes that favor their business model [42][43] Question: Capacity constraints and market share - Management clarified that Canadian operations remain a priority, balancing international demand with commitments in Canada [49] - The company regained its number one flower share position in January and expects continued growth in 2026 [50]

Financial Data and Key Metrics Changes - Village Farms reported a net income from continuing operations of $21 million or $0.19 per share, a $49 million improvement compared to the prior year [5] - Adjusted EBITDA from continuing operations reached $50 million, an increase of $48 million, while cash flow from continuing operations improved to $58 million, up $44 million compared to 2024 [5][26] - The company achieved a year-over-year growth in net sales of 9%, totaling just shy of $50 million for Q4 [13][25] Business Line Data and Key Metrics Changes - Canadian cannabis sales grew by 10% year-over-year, with international export sales increasing nearly 400% [15][27] - Retail branded sales in Canada were flat compared to Q4 last year, but gross margins improved year-over-year, reaching 43% [15][28] - The Netherlands operations contributed $3.3 million in sales for Q4, with adjusted EBITDA of $700,000 [31] Market Data and Key Metrics Changes - The company maintained a top five overall market share position in Canada and held the number one position in dried flower as of the end of last month [15] - International export sales increased more than six-fold, benefiting from the company's leadership position as one of the largest EU GMP-certified cannabis operators [4] Company Strategy and Development Direction - Village Farms is focused on improving margin performance, profitability, and cash generation to enable additional growth investments [5] - The company is investing in capacity expansion projects in Canada and the Netherlands, with expectations of significant increases in production and revenue [20][23] - The transition to privatize the legacy produce business reflects confidence in the cannabis business's ability to stand on its own [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand fundamentals domestically and internationally, expecting to drive profitable growth in 2026 and beyond [19] - The company anticipates returning to sequential growth in international exports in Q1 and plans to ship to multiple new jurisdictions [19] - Management acknowledged temporary supply constraints but emphasized the underlying strength of the business [19] Other Important Information - The company ended the year with approximately $86 million in cash and completed a $3 million share repurchase during Q4 [24][34] - The ongoing share repurchase program reflects a balanced approach to capital allocation aimed at driving returns to shareholders [34] Q&A Session Summary Question: Share repurchases and capital allocation - Management indicated that share repurchases reflect confidence in cash generation and do not impact operational opportunities [40] Question: Growth in the German market - Management noted that regulatory uncertainties had caused a decline in imports but expected growth to return in Q1, with increasing demand anticipated [42][43] Question: Capacity constraints and market share aspirations - Management clarified that Canada remains the primary market, balancing international demand with commitments in Canada [49] - The company regained its number one flower share position in January and expects continued growth in 2026 [50]

Financial Data and Key Metrics Changes - The company reported a net income from continuing operations of $21 million or $0.19 per share, a $49 million improvement compared to the prior year [5] - Adjusted EBITDA from continuing operations reached $50 million, an improvement of $48 million year-over-year [5] - Cash flow from continuing operations was $58 million, an increase of $44 million compared to 2024 [5] - For Q4, net sales grew by 9% year-over-year to just shy of $50 million, with net income from operations at $2.3 million and adjusted EBITDA of $8.6 million [13][26] Business Line Data and Key Metrics Changes - Global cannabis sales increased by 70% year-over-year, with significant contributions from the Netherlands business [4] - Canadian cannabis sales for Q4 were $52.7 million, a 10% increase compared to the same quarter last year, driven by international medicinal exports which grew by 384% [27] - Retail branded sales in Canada were flat compared to Q4 last year, but gross margins improved to 43%, above the target range of 30%-40% [14][28] Market Data and Key Metrics Changes - The company maintained a top five overall market share position in Canada and held the number one position in dried flower as of the end of the last month [14] - International export sales increased more than six-fold, benefiting from the company's leadership position as one of the largest EU GMP-certified cannabis operators [4] Company Strategy and Development Direction - The company is focused on improving margin performance, profitability, and cash generation to enable further growth investments [5] - The strategy includes a methodical approach to scaling operations, with a focus on high-margin products and international expansion [6][12] - The company is investing in capacity expansion projects in Canada and the Netherlands to meet increasing demand [20][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying fundamentals of the business, with strong demand domestically and internationally [19] - The company expects to return to sequential growth in international exports in Q1 and anticipates shipping to multiple new jurisdictions [19] - Management highlighted the importance of maintaining a balanced approach to capital allocation while pursuing growth opportunities [36] Other Important Information - The company ended the year with approximately $86 million in cash and a strong net cash position of $53 million [33] - The company has been active in its share repurchase program, purchasing nearly 813,000 shares at an aggregate cost of $3 million during Q4 [33] Q&A Session Summary Question: Share repurchases and capital allocation - Management indicated that share repurchases reflect confidence in cash generation and do not impact operational opportunities [39] Question: Growth in the German market - Management acknowledged a decline in import volumes but expects growth to resume, citing regulatory changes that favor their business model [41][42] Question: Capacity constraints and market share aspirations - Management clarified that Canadian operations remain a priority, balancing international demand with commitments in Canada [47] - The company regained its number one flower share position in January and expects continued growth in 2026 [48]

Financial Performance - Consolidated net income from continuing operations for the full year 2025 reached $21.0 million, or $0.19 per share, with adjusted EBITDA of $49.9 million and operating cash flow of $58.1 million[4]. - Q4 consolidated net sales increased by 9% year-over-year to $49.6 million, with Canadian cannabis sales up 10% and international export cannabis sales soaring by 384%[4]. - Q4 net income from continuing operations improved to $2.3 million, or $0.02 per share, compared to a net loss of $7.5 million in the prior year[4]. - Total sales for the year ended December 31, 2025, reached $215.937 million, with cannabis sales contributing $163.710 million from the U.S. and $26.295 million from Canada[27]. - Net income for the year ended December 31, 2025, was CAD $37.0 million, compared to a loss of CAD $4.8 million in 2024[20]. - The company reported a net loss attributable to shareholders of $32,441,000 for the year, an improvement from a loss of $35,851,000 in 2024[40]. Operational Efficiency - Canadian cannabis gross margin for Q4 was reported at 43%, with adjusted EBITDA of $9.8 million, representing 25.8% of sales[4]. - Adjusted EBITDA from Continuing Operations for Q4 2025 was CAD $14.3 million, compared to a loss of CAD $9.1 million in Q4 2024[20]. - Adjusted EBITDA from continuing operations for the year was $49,852,000, compared to $7,374,000 in 2024, indicating a substantial increase in profitability[40]. - The cost of sales for the same period in 2025 was $30,395,000, compared to $39,886,000 in 2024, indicating a reduction of about 23.9%[25]. - Gross Profit for Q4 2025 was CAD $22.7 million, significantly up from CAD $1.0 million in Q4 2024, reflecting a 2170% increase[20]. Market Expansion - The Delta 2 expansion project commenced cultivation on March 2, 2026, expected to yield an additional 15 tonnes of production capacity in 2026[4]. - The Netherlands expansion is on track, with the first grow rooms expected to be planted by the end of Q1 2026 and full facility completion anticipated by the end of Q2 2026, aiming for an annual production capacity of approximately 10 tonnes[4]. - International export sales increased significantly, driven by strong demand in Germany and other international markets, positioning the company as a leading exporter of medical cannabis to Europe[4]. - The company is focusing on market expansion and new product development to drive future growth, particularly in the cannabis and clean energy sectors[25]. Financial Health - The company ended 2025 with $86 million in cash and has completed $6.7 million in share repurchases since Q3 2025[4]. - Cash and cash equivalents increased to $81,189,000 as of December 31, 2025, up from $24,631,000 in 2024, indicating stronger liquidity[38]. - Total current assets rose to $154,437,000 in 2025, compared to $116,019,000 in 2024, reflecting growth in operational capacity[38]. - The company’s total liabilities decreased to $113,034,000 in 2025 from $125,348,000 in 2024, indicating improved financial health[38]. Strategic Investments - The company is focused on maintaining a balanced approach to capital allocation, considering both organic and acquisitive investments for growth in 2026[4]. - The company anticipates continued growth in the greenhouse vegetable and cannabis sectors, supported by strategic investments and market expansion plans[35]. - The company is focusing on expanding its cannabis production capabilities and exploring new market opportunities in clean energy sectors[27][28]. Challenges and Cautions - The company cautioned that results for the periods ended December 31, 2025, and 2024 may not be indicative of future performance[24]. - The company reported a significant impairment of goodwill and intangible assets amounting to $11.939 million in 2024[28]. - The foreign currency exchange loss for the year ended December 31, 2025, was $1,677,000, compared to a gain of $2,635,000 in 2024, indicating a negative shift in currency impacts[30].

Core Insights - Village Farms International reported strong financial performance for Q4 2025, achieving record levels in profitability, gross margin, and cash flow from operations, indicating a transformational year for the company [2][3]. Financial Performance - Consolidated net income from continuing operations for the full year 2025 was $21.0 million, or $0.19 per share, with adjusted EBITDA from continuing operations at $49.9 million and operating cash flow of $58.1 million [3][8]. - Q4 2025 consolidated net sales increased by 9% year-over-year to $49.6 million, with Canadian cannabis sales up 10% and international export cannabis sales soaring by 384% [3][8]. - The company ended 2025 with $86 million in cash and has completed $6.7 million in share repurchases since Q3 2025 [3][8]. Operational Highlights - The company commenced cultivation in the first half of its Delta 2 expansion in Canada, expected to yield an additional 15 tonnes of production capacity in 2026 [2][3]. - The Netherlands facility is operating at full capacity, with plans to scale operations for a Phase II facility in Groningen, anticipated to reach an annual production capacity of approximately 10 tonnes [2][3]. - International export sales increased significantly, driven by demand in Germany and other international markets, positioning the company as a leading exporter of medical cannabis to Europe [2][3]. Market Position and Strategy - Village Farms maintains a top five market share position in Canada and is the number one in dried flower as of February 2026, despite planned reductions in lower-margin SKUs [2][3]. - The company is focused on capital allocation for organic and acquisitive investments while enhancing shareholder value through ongoing share repurchases [2][3]. - New product innovations, including unique packaging solutions, have been introduced to the Canadian market, contributing to the company's competitive edge [2][3].